- In patients with chronic lymphocytic leukemia (CLL), ibrutinib delivered favorable response and survival outcomes across treatment lines.
- Among patients who discontinued ibrutinib, those receiving ibrutinib in earlier treatment lines experienced better survival outcomes.
Why this matters
- Ibrutinib discontinuation has been associated with inferior survival in patients with high-risk CLL who have experienced multiple relapses.
- Study to investigate outcomes with ibrutinib for CLL by treatment line or discontinuation/after discontinuation.
- Data sources:
- RESONATE study (n=135) in patients aged ≥65 years with treatment-naive disease.
- RESONATE 2 study (n=136) in patients who had received ≥1 prior therapy.
- Funding: Pharmacyclics LLC, an AbbVie Company.
- Median PFS and OS were not reached regardless of number of prior lines of therapy.
- Overall response rate (ORR):
- 0 prior therapies: 92%.
- 1-2 prior therapies: 96%.
- ≥3 prior therapies: 88%.
- 3.7% of treatment-naive patients and 20% of relapsed/refractory patients discontinued ibrutinib because of progressive disease (PD).
- Median OS after discontinuation:
- 0 prior therapies: NR (95% CI, 5.9 months-not estimable [NE]).
- 1-2 prior therapies: 9.3 (95% CI, 7.8-22) months.
- ≥3 prior therapies: 8.9 (95% CI, 4.3-NE) months.
- Retrospective data.